Financial Data and Key Metrics Changes - In 2025, the company's revenue increased to CNY 18.6 million from 0 in the previous year, primarily due to an upfront payment from a licensing agreement with Joincare Group [20] - Other income decreased by CNY 72.6 million or 51.3% to CNY 68.8 million compared to CNY 141.4 million in 2024, mainly due to lower bank interest income and changes in government grant income [21] - Research and development expenses declined by 14.8% to CNY 212.9 million from CNY 249.8 million in 2024, reflecting cost control measures [22] - Administrative expenses were CNY 199.5 million, a decline of 28.5% compared to CNY 153.2 million in 2024, attributed to lower employee costs and organizational optimization [23] - As of December 31, 2025, cash and cash equivalents were CNY 1,941 million, expected to support operations beyond 2028 [22] Business Line Data and Key Metrics Changes - The company focused on advancing its HBV functional cure program, which remains its top clinical priority, with key data reported and studies progressing towards registrational pathways [3][4] - The partnership with Joincare Group for soralimixin allows the company to prioritize resources on HBV programs while advancing non-HBV assets [4][5] Market Data and Key Metrics Changes - The company is leveraging China's strong research ecosystem to enhance its discovery capabilities, establishing labs in Beijing and Shanghai to support early-stage drug discovery [9][36] - The company is exploring partnership opportunities for its HIV program and other non-core assets, indicating a strategic approach to market engagement [32][38] Company Strategy and Development Direction - The company aims to maintain strong alignment with shareholder interests by reducing senior management's annual bonuses to approximately one quarter of their original level [5] - The strategy includes a disciplined partnering approach for non-HBV assets while focusing on areas with the strongest near-term opportunities [10][11] - The company plans to introduce new programs from its discovery platform and define its development strategy around them [24][38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the HBV program's potential, expecting important data to emerge later this year to inform the next stage of development [40] - The company is aware of the competitive landscape and aims to differentiate its offerings while exploring the potential of its expanded discovery capabilities [29][36] Other Important Information - The company has made significant investments in building its internal research capabilities and integrating AI-enabled discovery tools into its workflow [8][9] - The company is open to both internal development and partnerships for its discovery programs, depending on expertise and market potential [38] Q&A Session Summary Question: Expectations for data from ENRICH and ENHANCE studies - Management expects data to emerge throughout the year, looking for immunologic priming effects and enhanced response rates in the ENRICH study, and a 10% or better response in the ENHANCE study compared to previous results [26][27][28] Question: Focus areas for expanded discovery capabilities - The company is expanding beyond infectious diseases to include chronic diseases with unmet medical needs, with specific areas to be disclosed later [30][31] Question: Updates on partnering strategy for non-core assets - The company continues to explore partnerships for its HIV program and other assets, with ongoing discussions with potential partners [32]

Core Insights - The article discusses the results of Brii Biosciences' Phase 2 ENSURE study, which evaluates the efficacy and safety of the siRNA elebsiran in combination with pegylated interferon alfa (PEG-IFN) for chronic hepatitis B infection, alongside the potential role of the HBV therapeutic vaccine BRII-179 [1][3][4]. Study Design and Results - The ENSURE study was conducted in two parts with virally suppressed chronic HBV patients, comparing PEG-IFN monotherapy to a combination of PEG-IFN and elebsiran [3]. - In Cohorts 1-3, HBsAg loss was observed in 21.1% of participants receiving elebsiran 200 mg + PEG-IFN and 33.3% in those receiving elebsiran 100 mg + PEG-IFN, compared to 5.6% in the PEG-IFN monotherapy group [9]. - In Cohort 4, 29.0% of participants achieved HBsAg loss, with a higher response rate of 42.1% among BRII-179 anti-HBs responders compared to 8.3% in non-responders [9]. Therapeutic Implications - The study's design provides a benchmark for future siRNA development towards achieving an HBV functional cure, highlighting the clinical benefit of elebsiran over monotherapy [4]. - The findings suggest that BRII-179 may enhance immune system responsiveness, leading to improved outcomes in patients with high baseline HBsAg levels [6]. Safety Profile - The combination therapy of elebsiran and PEG-IFN was reported to be generally safe and well tolerated across all cohorts [9]. Company Background - Brii Biosciences is focused on developing therapies for infectious diseases, particularly hepatitis B, and has a pipeline that includes innovative candidates like elebsiran and BRII-179 [13].

Core Insights - Brii Biosciences Limited is advancing its hepatitis B virus (HBV) functional cure program through multiple Phase 2b trials, including ENRICH and ENHANCE studies, aiming for higher cure rates [2][5] - The company has entered a strategic collaboration with Joincare Pharmaceutical Group for the development of soralimixin in Greater China, enhancing its portfolio and partnership strategy [2][8] - Brii Bio maintains a strong cash position of US$289.9 million, sufficient to support its late-stage development plans and early discovery initiatives [3][13] HBV Program Updates - The ENSURE study shows that prior treatment with BRII-179 and elebsiran can induce robust anti-HBs responses, with 61% of patients achieving HBsAg seroclearance at Week 48 [6] - The company is assessing BRII-179 in two additional Phase 2b trials, ENRICH and ENHANCE, to identify optimal combination regimens for HBV treatment [12] - Data from the ongoing studies are expected to inform the next phase of the clinical strategy for HBV functional cure [9][12] Financial Performance - As of June 30, 2025, the company's cash and cash equivalents were RMB2,075.3 million, a decrease of 14.0% from the previous year, primarily due to R&D expenditures [13] - Research and development expenses for the first half of 2025 were RMB117.0 million, reflecting a decrease of 7.3% compared to the same period in 2024, indicating effective cost control measures [13][20] - Administrative expenses decreased by 26.0% to RMB58.2 million, attributed to reduced employee costs and facility-related expenses [20] Strategic Outlook - Brii Bio is committed to delivering innovative therapies for infectious diseases, with a focus on achieving a functional cure for HBV [9] - The company plans to continue expanding its internal discovery capabilities and partnerships to drive sustainable growth [4][10] - Key data readouts from the HBV functional cure program are expected in the first half of 2026, which will shape future clinical strategies [9]

Core Insights - Brii Biosciences Limited announced new data from its Phase 2 ENSURE study at the APASL 2025 meeting, highlighting the potential of its therapies for chronic HBV infection [1][5] Study Design and Objectives - The ENSURE study is a multicenter, open-label Phase 2 trial designed to evaluate the efficacy of elebsiran in combination with pegylated interferon alpha (PEG-IFNα) in chronic HBV patients [2] - Cohort 4 included participants who previously received BRII-179, a therapeutic vaccine, to assess the combination treatment's effectiveness [2] Key Findings - In Cohort 4, 55.6% of BRII-179 responders achieved HBsAg seroclearance at Week 24, compared to only 10% in non-responders, indicating BRII-179's potential as a predictive tool for treatment response [3][10] - Data from Cohorts 1-3 showed higher rates of HBsAg loss and seroconversion in participants receiving elebsiran with PEG-IFNα compared to those receiving PEG-IFNα alone [4][11] Expert Commentary - Dr. Grace Lai-Hung Wong emphasized that the positive results from Cohort 4 support the potential of BRII-179 in identifying patients likely to respond to curative therapies [5] - David Margolis, MD, noted that the findings reinforce the strategy of using BRII-179 to enhance functional cure rates while minimizing unnecessary treatment costs for less responsive patients [5] Broader Context - Chronic HBV infection affects over 254 million people globally, with significant mortality rates, particularly in regions like China where 87 million are chronically infected [9] - BRII-179 is a novel immunotherapeutic candidate designed to enhance immune responses against HBV, and it has received Breakthrough Therapy Designation from the CDE in China [9][10] Future Directions - Brii Bio is advancing multiple combination studies involving BRII-179 and elebsiran, with key data expected to be presented at scientific conferences throughout 2025 [8][10]